EP1333862A2 - Verfahren und pharmazeutische zusammensetzungen zur verbesserung der implantation von embryos - Google Patents
Verfahren und pharmazeutische zusammensetzungen zur verbesserung der implantation von embryosInfo
- Publication number
- EP1333862A2 EP1333862A2 EP01978796A EP01978796A EP1333862A2 EP 1333862 A2 EP1333862 A2 EP 1333862A2 EP 01978796 A EP01978796 A EP 01978796A EP 01978796 A EP01978796 A EP 01978796A EP 1333862 A2 EP1333862 A2 EP 1333862A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- heparanase
- embryo
- effective amount
- contacting
- mature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 108
- 238000002513 implantation Methods 0.000 title claims description 43
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 33
- 210000002257 embryonic structure Anatomy 0.000 title claims description 27
- 108010037536 heparanase Proteins 0.000 claims abstract description 192
- 102100024025 Heparanase Human genes 0.000 claims abstract description 184
- 210000001161 mammalian embryo Anatomy 0.000 claims abstract description 92
- 210000004291 uterus Anatomy 0.000 claims abstract description 79
- 230000032692 embryo implantation Effects 0.000 claims abstract description 32
- 210000002459 blastocyst Anatomy 0.000 claims description 33
- 238000000338 in vitro Methods 0.000 claims description 28
- 230000004720 fertilization Effects 0.000 claims description 17
- 239000004480 active ingredient Substances 0.000 claims description 9
- 230000012010 growth Effects 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 235000015097 nutrients Nutrition 0.000 claims description 4
- 101100380241 Caenorhabditis elegans arx-2 gene Proteins 0.000 claims 1
- 101150092805 actc1 gene Proteins 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 52
- 229920002971 Heparan sulfate Polymers 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 30
- 210000002744 extracellular matrix Anatomy 0.000 description 26
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 24
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 24
- 102000004190 Enzymes Human genes 0.000 description 20
- 108090000790 Enzymes Proteins 0.000 description 20
- 229940088598 enzyme Drugs 0.000 description 20
- 210000001519 tissue Anatomy 0.000 description 20
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 18
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 18
- 230000035935 pregnancy Effects 0.000 description 18
- 230000008569 process Effects 0.000 description 15
- 108090000054 Syndecan-2 Proteins 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000003102 growth factor Substances 0.000 description 13
- 210000002993 trophoblast Anatomy 0.000 description 13
- 229920002683 Glycosaminoglycan Polymers 0.000 description 12
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 11
- 241000699660 Mus musculus Species 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 230000009261 transgenic effect Effects 0.000 description 11
- 238000011830 transgenic mouse model Methods 0.000 description 11
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 229960002897 heparin Drugs 0.000 description 10
- 102000016611 Proteoglycans Human genes 0.000 description 9
- 108010067787 Proteoglycans Proteins 0.000 description 9
- 230000009545 invasion Effects 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 230000013011 mating Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 230000008774 maternal effect Effects 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 230000027326 copulation Effects 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 208000000509 infertility Diseases 0.000 description 5
- 230000036512 infertility Effects 0.000 description 5
- 231100000535 infertility Toxicity 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 210000001550 testis Anatomy 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108700019146 Transgenes Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000000593 degrading effect Effects 0.000 description 4
- 150000002016 disaccharides Chemical group 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 210000002308 embryonic cell Anatomy 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 210000003101 oviduct Anatomy 0.000 description 4
- 210000004681 ovum Anatomy 0.000 description 4
- 210000002826 placenta Anatomy 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 238000011748 CB6F1 mouse Methods 0.000 description 3
- 102100032912 CD44 antigen Human genes 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 108010062466 Enzyme Precursors Proteins 0.000 description 3
- 102000010911 Enzyme Precursors Human genes 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Chemical group O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000004157 Hydrolases Human genes 0.000 description 3
- 108090000604 Hydrolases Proteins 0.000 description 3
- 102000007547 Laminin Human genes 0.000 description 3
- 108010085895 Laminin Proteins 0.000 description 3
- 108090000856 Lyases Proteins 0.000 description 3
- 102000004317 Lyases Human genes 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000002469 basement membrane Anatomy 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000003679 cervix uteri Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 150000004676 glycans Polymers 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 102000006495 integrins Human genes 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- -1 oxonium ion Chemical class 0.000 description 3
- 230000028742 placenta development Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 150000004804 polysaccharides Polymers 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000005670 sulfation reaction Methods 0.000 description 3
- 108091016585 CD44 antigen Proteins 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 206010015866 Extravasation Diseases 0.000 description 2
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 2
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 2
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 2
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 2
- 108010086677 Gonadotropins Proteins 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical group O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 230000007698 birth defect Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000004709 cell invasion Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000002357 endometrial effect Effects 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000006345 epimerization reaction Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000036251 extravasation Effects 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- 239000002622 gonadotropin Substances 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000008611 intercellular interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000003076 paracrine Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 2
- 108010047481 uterine luminal fluid proteins Proteins 0.000 description 2
- 210000001177 vas deferen Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 101710122462 65 kDa protein Proteins 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102100034561 Alpha-N-acetylglucosaminidase Human genes 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 101001057129 Bacillus cereus Enterotoxin Proteins 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010060309 Glucuronidase Proteins 0.000 description 1
- 102000053187 Glucuronidase Human genes 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 108010022901 Heparin Lyase Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000004627 Iduronidase Human genes 0.000 description 1
- 108010003381 Iduronidase Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000005755 Intercellular Signaling Peptides and Proteins Human genes 0.000 description 1
- 108010070716 Intercellular Signaling Peptides and Proteins Proteins 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 101710180643 Leishmanolysin Proteins 0.000 description 1
- 208000035752 Live birth Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100219349 Mus musculus Cdh11 gene Proteins 0.000 description 1
- 101000700655 Mycobacterium leprae (strain TN) Serine-rich antigen Proteins 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010071368 Psychological trauma Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102100032953 Trophinin Human genes 0.000 description 1
- 101710148378 Trophinin Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 108010009380 alpha-N-acetyl-D-glucosaminidase Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 238000007068 beta-elimination reaction Methods 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003710 calcium ionophore Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000035289 cell-matrix adhesion Effects 0.000 description 1
- 210000003570 cell-matrix junction Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000003785 decidua Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003413 degradative effect Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000002367 endolytic effect Effects 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000646 extraembryonic cell Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108010038082 heparin proteoglycan Proteins 0.000 description 1
- 108010006406 heparinase II Proteins 0.000 description 1
- 108010083213 heparitinsulfate lyase Proteins 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- IAJILQKETJEXLJ-LECHCGJUSA-N iduronic acid Chemical compound O=C[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-LECHCGJUSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000009027 insemination Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000010311 mammalian development Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 208000008634 oligospermia Diseases 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 108010049224 perlecan Proteins 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 210000000251 trophoblastic cell Anatomy 0.000 description 1
- 230000001573 trophoblastic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000005167 vascular cell Anatomy 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 238000007879 vasectomy Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000004340 zona pellucida Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24085700P | 2000-10-17 | 2000-10-17 | |
US240857P | 2000-10-17 | ||
PCT/IL2001/000950 WO2002032283A2 (en) | 2000-10-17 | 2001-10-15 | Methods of and pharmaceutical compositions for improving implantation of embryos |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1333862A2 true EP1333862A2 (de) | 2003-08-13 |
EP1333862A4 EP1333862A4 (de) | 2004-08-18 |
Family
ID=22908221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01978796A Withdrawn EP1333862A4 (de) | 2000-10-17 | 2001-10-15 | Verfahren und pharmazeutische zusammensetzungen zur verbesserung der implantation von embryos |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1333862A4 (de) |
AU (1) | AU2002210887A1 (de) |
WO (1) | WO2002032283A2 (de) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6699672B1 (en) | 1997-09-02 | 2004-03-02 | Insight Biopharmaceuticals Ltd. | Heparanase specific molecular probes and their use research and medical applications |
AU2002216341A1 (en) * | 2000-12-19 | 2002-07-01 | Insight Strategy And Marketing Ltd. | The use of ecm degrading enzymes for the improvement of cell transplantation |
CN100384481C (zh) * | 2004-11-03 | 2008-04-30 | 上海市计划生育科学研究所 | 胚泡着床相关因子及其用途 |
CN100415299C (zh) * | 2004-12-22 | 2008-09-03 | 上海市计划生育科学研究所 | 胚泡着床相关因子及其用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991002977A1 (en) * | 1989-08-23 | 1991-03-07 | Hadassah Medical Organization | Wound healing preparations containing heparanase |
WO1999011798A1 (en) * | 1997-09-02 | 1999-03-11 | Insight Strategy & Marketing Ltd. | Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells |
WO1999021975A1 (en) * | 1997-10-28 | 1999-05-06 | The Australian National University | Isolated nucleic acid molecule encoding mammalian endoglucuronidase and uses therefor |
WO2000052149A1 (en) * | 1999-03-02 | 2000-09-08 | Insight Strategy & Marketing Ltd. | Introducing a biological material into a patient |
-
2001
- 2001-10-15 EP EP01978796A patent/EP1333862A4/de not_active Withdrawn
- 2001-10-15 WO PCT/IL2001/000950 patent/WO2002032283A2/en not_active Application Discontinuation
- 2001-10-15 AU AU2002210887A patent/AU2002210887A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991002977A1 (en) * | 1989-08-23 | 1991-03-07 | Hadassah Medical Organization | Wound healing preparations containing heparanase |
US5362641A (en) * | 1989-08-23 | 1994-11-08 | Hadassah Medical Organization Kiryat Hadassah | Heparanase derived from human Sk-Hep-1 cell line |
WO1999011798A1 (en) * | 1997-09-02 | 1999-03-11 | Insight Strategy & Marketing Ltd. | Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells |
WO1999021975A1 (en) * | 1997-10-28 | 1999-05-06 | The Australian National University | Isolated nucleic acid molecule encoding mammalian endoglucuronidase and uses therefor |
WO2000052149A1 (en) * | 1999-03-02 | 2000-09-08 | Insight Strategy & Marketing Ltd. | Introducing a biological material into a patient |
Non-Patent Citations (5)
Title |
---|
CARSON DANIEL D ET AL: "Mucin and proteoglycan functions in embryo implantation" BIOESSAYS, vol. 20, no. 7, July 1998 (1998-07), pages 577-583, XP002284179 ISSN: 0265-9247 * |
DEMPSEY L A ET AL: "Heparanase expression in invasive trophoblasts and acute vascular damage" GLYCOBIOLOGY, IRL PRESS,, GB, vol. 10, no. 5, May 2000 (2000-05), pages 467-475, XP002232893 ISSN: 0959-6658 * |
DEMPSEY L A ET AL: "Heparanase, a potential regulator of cell-matrix interactions." TRENDS IN BIOCHEMICAL SCIENCES. ENGLAND AUG 2000, vol. 25, no. 8, August 2000 (2000-08), pages 349-351, XP004215172 ISSN: 0968-0004 * |
See also references of WO0232283A2 * |
VLODAVSKY I ET AL: "EXPRESSION OF HEPARANASE BY PLATELETS AND CIRCULATING CELLS OF THE IMMUNE SYSTEM: POSSIBLE INVOLVEMENT IN DIAPEDESIS AND EXTRAVASATION" INVASION METASTASIS, S. KARGER, BASEL, CH, vol. 12, no. 2, March 1992 (1992-03), pages 112-127, XP001106180 ISSN: 0251-1789 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002032283A3 (en) | 2002-10-31 |
WO2002032283A2 (en) | 2002-04-25 |
AU2002210887A1 (en) | 2002-04-29 |
EP1333862A4 (de) | 2004-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060008892A1 (en) | Methods of and pharmaceutical compositions for improving implantation of embryos | |
Holm et al. | Embryo viability, duration of gestation and birth weight in sheep after transfer of in vitro matured and in vitro fertilized zygotes cultured in vitro or in vivo | |
US11185348B2 (en) | Method of in vitro fertilization with delay of embryo transfer and use of peripheral blood mononuclear cells | |
Hagemann et al. | In vitro and early in vivo development of sheep gynogenones and putative androgenones | |
Park et al. | SPAM1/HYAL5 double deficiency in male mice leads to severe male subfertility caused by a cumulus‐oocyte complex penetration defect | |
Revel et al. | Heparanase improves mouse embryo implantation | |
EP1333862A2 (de) | Verfahren und pharmazeutische zusammensetzungen zur verbesserung der implantation von embryos | |
RU2682318C2 (ru) | Композиции и способы для улучшения молочной продуктивности и репродуктивного здоровья млекопитающих, основанные на применении IL-8 | |
Hossein et al. | Cloning missy: obtaining multiple offspring of a specific canine genotype by somatic cell nuclear transfer | |
Flores-Foxworth et al. | Interspecific transfer of IVM IVF-derived red sheep (Ovis orientalis gmelini) embryos to domestic sheep (Ovis aries) | |
Melican et al. | Repeat superovulation, non-surgical embryo recovery, and surgical embryo transfer in transgenic dairy goats | |
Ferguson et al. | 136 evidence of a direct effect of P4 on IVF-derived bovine 8-cell embryos | |
Abe et al. | 129 RESPIRATION ACTIVITY OF BOVINE EMBRYOS CULTURED IN SERUM-FREE AND SERUM-CONTAINING MEDIA | |
Cardullo et al. | Function of the egg's extracellular matrix | |
RU2736131C2 (ru) | Композиции и способы для улучшения молочной продуктивности и репродуктивного здоровья млекопитающих, основанные на применении il-8 | |
Murakami et al. | Transfer of Inner Cell Mass Cells Derived from Bovine Nuclear Transfer Embryos into the Trophoblast of Bovine In Vitro–Produced Embryos | |
Poleszczuk et al. | 148 AN EFFECT OF MELATONIN ON DEVELOPMENT OF BOVINE EMBRYOS CULTURED IN VITRO UNDER OPTIMAL OR ENHANCED OXYGEN TENSIONS | |
Ock et al. | 145 COMPARISON OF DEVELOPMENT AND QUALITY OF PORCINE EMBRYOS CULTURED IN DIFFERENT OXYGEN CONCENTRATIONS | |
Daniaux et al. | 133 INSULIN, TRANSFERRIN AND SELENIUM WITH OR WITHOUT BSA IN A SERUM-FREE CULTURE SYSTEM FOR BOVINE EMBRYO, AND ITS SUITABILITY FOR EMBRYOS CULTURED IN SMALL GROUPS | |
Goda et al. | 137 Effect of flunixin meglumine in co-culture medium on the development of in vitro matured and fertilized bovine embryos | |
De La Torre-Sanchez et al. | 135 REGULATION OF GLUCOSE METABOLISM TO DECREASE LIPID CONTENT OF IN VIRTO-PRODUCED BOVINE EMBRYOS | |
Gandolfi et al. | Expression pattern of Nanog and Par3 genes in in-vitro-derived bovine embryos | |
Wongsrikeao et al. | 151 EFFECTS OF HEXOSES SUPPLEMENTED IN THE MATURATION AND PRE IMPLANTATION MEDIUM ON THE IN VITRO DEVELOPMENT OF PORCINE OOCYTES | |
Mello et al. | 142 IN VITRO DEVELOPMENT OF BOVINE EMBRYOS CULTURED IN KSOM, CR1AA, OR KSOM/CR1aa | |
Kim et al. | 140 EXPRESSION OF LEPTIN LIGAND AND RECEPTOR AND EFFECT OF EXOGENOUS LEPTIN SUPPLEMENTATION ON IN VITRO DEVELOPMENT OF PORCINE IN VITRO FERTILIZED AND SOMATIC CELL NUCLEAR TRANSFER EMBRYOS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030513 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7C 07H 21/04 B Ipc: 7C 07H 21/02 B Ipc: 7C 12N 15/86 B Ipc: 7C 12N 15/85 B Ipc: 7C 12N 15/11 B Ipc: 7A 61K 38/47 A |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040701 |
|
17Q | First examination report despatched |
Effective date: 20050329 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: INSIGHT BIOPHARMACEUTICALS LTD. |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20080411 |